Italia markets closed

uniQure N.V. (QURE)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
20,78+0,40 (+1,96%)
Alla chiusura: 04:00PM EDT
20,22 -0,56 (-2,69%)
Dopo ore: 04:05PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente20,38
Denaro20,75 x 1200
Lettera20,77 x 800
Min-Max giorno19,62 - 20,79
Intervallo di 52 settimane12,52 - 38,80
Media Volume746.003
Beta (5 anni mensile)1,00
Rapporto PE (ttm)2,73
EPS (ttm)7,60
Prossima data utili24 ott 2022 - 28 ott 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A49,56
  • GlobeNewswire

    uniQure Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress

    ~ Announced 12-month data on the lower-dose cohort of AMT-130 in Huntington’s disease showed the investigative gene therapy was generally well tolerated at this dose with a mean reduction of 53.8% of mutant Huntingtin protein (mHTT) observed in cerebral spinal fluid (CSF) ~ ~ Announced postponement of AMT-130 higher-dose procedures due to recent suspected unexpected severe adverse reactions at this dose; Lower-dose procedures are not affected and no impact is expected on anticipated data readout

  • GlobeNewswire

    uniQure Announces Update on Low-Dose Cohort in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease

    Bar Chart Bar Chart ~ Treatment generally well-tolerated with no significant safety issues related to AMT-130 in treated patients through one year of follow-up ~ ~ A mean reduction of 53.8% of mutant HTT (mHTT) observed in cerebral spinal fluid (CSF) at 12 months in evaluable patients treated with AMT-130 ~ ~ Neurofilament Light Chain (NfL) in CSF near baseline at 12 months in patients treated with AMT-130 ~ ~ Biomarker and clinical data including 24-month follow-up in the low-dose U.S. cohort a

  • GlobeNewswire

    CORRECTION -- uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 22, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by uniQure N.V. (NASDAQ: QURE), please note that all the numbers have been updated. The corrected release follows: uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the Company granted equity awards to 22 employees as a material inducement to commencing